The Wake Forest School of Medicine Alzheimer’s Disease Core Center offers patients a chance to participate in clinical trials that may impede the development of mild cognitive impairment or Alzheimer’s disease and help the functioning of the aging brain.
Alzheimer’s Disease Clinical Core (ADCC)
The Alzheimer’s Disease Prevention Participant Repository is an observational study that will be used to identify and characterize early risk factors that predict memory decline and dementia in adults, with or without early signs of memory impairment.
Study of Nasal Insulin to Fight Forgetfulness – Short-Acting Insulin Aspart – 12 weeks (SNIFF-QUICK Study)
The purpose of this three-month research study is to find out whether insulin aspart improves memory when administered as a spray into the nasal passages of adults with mild memory impairment or early Alzheimer’s disease.
in Dementia Methylphenidate Trial 2 (ADMET II)
This 6 month study
investigates the efficacy of methylphenidate for the treatment of clinically
significant apathy in participants with Alzheimer’s disease.
AVID 18F-AV-1451: A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET
Imaging and Post-Mortem Assessment of Tau Pathology (AVID)
Pictures of the brain made using the study drug during
the life of study participants will be compared to results of brain autopsy
EMERGE Study / Biogen 221AD302 - A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease
The purpose of the study is to find out whether aducanumab has the potential to be a helpful treatment that slows down disease progression in subjects with early Alzheimer’s Disease (AD) by comparing it to placebo and to evaluate its safety (side effects), and to find out more about aducanumab. About 1350 people from150 research sites world-wide between 50 and 85 years old will take part in this 18 month study.
EXERT Study / Phase 3 Multi-Center Study of Therapeutic Effects of Exercise in Adults with Amnestic Mild Cognitive Impairment
The EXERT study will examine the effects of aerobic exercise on cognition, functional status, brain atrophy and blood flow, and cerebrospinal fluid biomarkers of Alzheimer’s disease in 300 adults with amnestic Mild Cognitive Impairment. Adults will be between 65 and 89 years old. Participants will be randomized to one of two interventions: supervised and structured moderate/high intensity aerobic training vs.stretching/balance control for 12 months, followed by a 6-month unsupervised extension.
ADNI-3: Alzheimer’s Disease Neuroimaging Initiative 2
ADNI 3 builds upon the successes of earlier ADNI phases to identify the earliest signs of AD and will help define the subtle changes that may take place in the brains of older people many years before overt symptoms of the disease appear. The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.
The purpose of this research study is to see if the investigational drug, LY3314814 can slow the progression of Alzheimer’s disease.
The purpose of this research study is to determine whether an investigational drug, JNJ-54861911 is safe and beneficial in treating participants who are at risk of developing Alzheimer's disease
The purpose of this study is to determine whether nicotine can improve symptoms of memory loss in people experiencing mild memory problems (referred to in this study as “mild cognitive impairment” or MCI).